Example: tourism industry
Sciences, Inc. at 1
emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue BIKTARVY. If appropriate, anti-hepatitis B therapy may be
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
-800 GILEAD5 or FDA at 1800 FDA 1088 or …
www.gilead.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZYDELIG safely and effectively. See full prescribing information
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.gilead.com3 full prescribing information warning: posttreatment acute exacerbation of hepatitis b and risk of drug resistance with use of truvada for hiv-1 pre-
AmBisome (amphotericin B) liposome for injection
www.gilead.com5 Pediatric and Elderly Patients The pharmacokinetics of amphotericin B after administration of AmBisome in pediatric and elderly patients has not been studied; however, AmBisome has
(incidence greater than or equal to 10%, Grades 2
www.gilead.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VIREAD safely and effectively. DSee full prescribing information …
for BIKTARVY. BIKTARVY ...
www.gilead.comGilead Sciences 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BIKTARVY safely and effectively.
AMENDED AND RESTATED LICENSE AGREEMENT …
www.gilead.comFinal Version 1 AMENDED AND RESTATED LICENSE AGREEMENT (TEMPLATE) This AMENDED AND RESTATED LICENSE AGREEMENT (the “Agreement”) is made as of July __, 2011 (the “Effective Date”) by and between Gilead Sciences, Inc. a
HIGHLIGHTS OF PRESCRIBING INFORMATION 4, 5, …
www.gilead.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION 4, 5, or 6 These highlights do not include all the information needed to use HARVONI ® safely and effectively. See full prescribing information
LETAIRIS for LETAIRIS ...
www.gilead.com2 FULL PRESCRIBING INFORMATION WARNING: EMBRYO-FETAL TOXICITY Do not administer Letairis to a pregnant female because it may cause fetal harm.
MEDICATION GUIDE ZYDELIG (zye-DEL-ig) …
www.gilead.comMEDICATION GUIDE ZYDELIG® (zye-DEL-ig) (idelalisib) tablets What is the most important information I should know about Zydelig? Zydelig can cause serious side effects that can lead to death, including:
HIGHLIGHTS OF PRESCRIBING INFORMATION should only be …
www.gilead.com1 INDICATIONS AND USAGE . 1.1 HIV-1 Infection . VIREAD ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric …
Related documents
United States Court of Appeals for the Federal Circuit
cafc.uscourts.govNov 30, 2021 · peutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof, and (b) one or more pharmaceutically acceptable excipients, wherein the therapeutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof is about 480 [milligrams] per day [(mg/day)]. Id. col. 27 ll. 59– 67 ...